A Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Neuroblastoma
  • Age: Between 1 years - 30 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients who are diagnosed with neuroblastoma or ganglioneuroblastoma (nodular).

You may not be eligible for this study if the following are true:

  • 1) Patients who have an INRG Stage L2 tumor without amplification of MYCN regardless of tumor histology.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.